Erratum: Effects of glycyrrhizic acid on 11-β-hydroxysteroid dehydrogenase (11-βHSD1 and 2) activities and HOMA-IR in rats at different treatment periods (Experimental and Clinical Endocrinology and Diabetes DOI:10.1055/s-0029-1237703);Effects of glycyrrhizic acid on 11-hydroxysteroid dehydrogenase (11HSD1 and 2) activities and HOMA-IR in rats at different treatment periods

Experimental and Clinical Endocrinology and Diabetes

Volumn 118, Issue 9, 2010, Pages 617-624

  Chia, Y Y ^a   Ton, S H ^a   Kadir, K B A ^a  

^a MONASH UNIVERSITY MALAYSIA   (Malaysia)

Author keywords

11 hydroxysteroid dehydrogenase; glucose; glycyrrhizic acid; insulin; type 2 diabetes mellitus

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE 1; 11BETA HYDROXYSTEROID DEHYDROGENASE 2; GLUCOSE; GLYCOGEN; GLYCYRRHIZIC ACID; INSULIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; GLUCOSE BLOOD LEVEL; GLYCOGEN SYNTHESIS; HISTOPATHOLOGY; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INTRAABDOMINAL FAT; KIDNEY; LIVER; MALE; NONHUMAN; PRIORITY JOURNAL; QUADRICEPS FEMORIS MUSCLE; RAT; SPRAGUE DAWLEY RAT;

EID: 77958125372     PISSN: 09477349     EISSN: 14393646     Source Type: Journal    
DOI: 10.1055/s-0030-1248125     Document Type: Erratum

References (35)

1. Ahren B, Pacini G. Importance of quantifying insulin secretion in relation to insulin sensitivity to accurately assess beta cell function in clinical studies. Eur J Endocrinol 2004 150 97-104
2. Anagnostis P, Athyros VG, Tziomalos K et al. The pathogenetic role of cortisol in the metabolic syndrome: A hypothesis. J Clin Endocrin Metab 2009 doi:10.1210/jc.2009-0370
3. Andrews RC, Rooyackers O, Walker BR. Effects of the 11-hydroxysteroid dehydrogenase inhibitor carbenoxolone on insulin sensitivity in men with type 2 diabetes. J Clin Endocrinol Metab 2003 88 (1) 285-291
4. Boyer R. Biochemistry laboratory: Modern theory and techniques. San Francisco: Benjamin Cummings 2006 272
5. Bujalska IJ, Walker EA, Hewison M et al. A switch in dehydrogenase to reductase activity of 11-hydroxysteroid dehydroganse type 1 upon differentiation of human omental adipose stromal cells. J Clin Endocrinol Metab 2002 87 (3) 1205-1210
6. Chapman KE, Seckl JR. 11HSD1, Inflammation, Metabolic disease and age-related cognitive (dys)function. Neurochem Res 2008 33 624-636
7. Draper N, Stewart PM. 11-hydroxysteroid dehydrogenase and the pre-receptor regulation of corticosteroid hormone action. J Endocrinol 2005 186 251-271
8. Gong R, Morris DJ, Brem AS. Variable expression of 11-hydroxysteroid dehydrogenase isoforms in vascular endothelial cells. Steroids 2008 73 1187-1196
9. Hammarstedtm A, Anderson CX, Rotter S et al. The effect of PPAR ligands on the adipose tissue in insulin resistance. Prostaglandins Leukot Essent Fatty Acids 2005 73 65-75
10. Harris HJ, Kotelevtsev Y, Mullins JJ et al. Intracellular regeneration of glucocorticoids by 11-hydroxysteroid dehydrogenase (11HSD)-1 plays a key role in regulation of the hypothalamic-pituitary-adrenal axis; analysis of 11HSD-1 deficient mice. Endocrinology 2001 142 114-120
11. Inoue H, Yokota H, Makino T et al. Bisphenol a glucuronide, a major metabolite in rat bile after liver perfusion. Drug Metab Dispos 2001 29 (8) 1084-1087
12. Isbrucker RA, Burdock GA. Risk and safety assessment on the consumption of licorice root (Glycyrrhiza sp. its extract and powder as a food ingredient, with emphasis on the pharmacology and toxicology of glycyrrhizin. Regul Toxicol Pharmacol 2006 46 167-192
13. Jang C, Obeyesekere VR, Diley RJ et al. Altered activity of 11-hydroxysteroid dehydrogenase types 1 and 2 in skeletal muscle confers metabolic protection in subjects with type 2 diabetes. 2007 92 (8) 2314-3320
14. Kiernan JA. Carbohydrate histochemistry. In Histological & Histochemical Methods: Theory & Practice. 3rd edition. Butterworth Heinemann, Oxford 1999 213-242
15. Krähenbuhl S, Hasler F, Frey BM et al. Kinetics and dynamics of orally administered 18-glycyrrhetinic acid in humans. J Clin Endocrinol Metab 1994 78 581-585
16. Lee MJ, Fried SK, Mundt SS et al. Depot-specific regulation of the conversion of cortisone to cortisol in human adipose tissue. Obesity 2008 16 (6) 1178-1185
17. Mahler RJ, Adler ML. Type 2 Diabetes Mellitus: Update on diagnosis, pathophysiology and treatment. J Clin Endocrinol Metab 1999 84 (4) 1165-1171
18. Masuzaki H, Paterson J, Shinyama H et al. A transgenic model of visceral obesity and the metabolic syndrome. Science 2001 294 2166-2170
19. Mori Y, Murakawa Y, Okada K et al. Effects of troglitazone on body fat distribution in type 2 diabetic patients. Diabetes Care 1999 22 908-912
20. Mussig K, Remer T, Haupt A et al. 11-hydroxysteroid dehydrogenase 2 activity is elevated in severe obesity and negatively associated with insulin sensitivity. Obesity 2008 16 (6) 1256-1260
21. Nwe KHH, Abdul Hamid, Morat PB et al. Differential regulation of the oxidative 11-hydroxysteroid dehydrogenase activity in testis and liver. Steroids 2000 65 40-45
22. Okuno A, Tamemoto H, Tobe K et al. Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats. J Clin Inves 1998 101 1354-1361
23. Okutucu B, Dincer A, Habib Ö et al. Comparison of five methods for determination of total plasma protein concentration. J Biochem Biophys Methods 2007 70 709-711
24. Ploeger B, Mensinga T, Sips A et al. The pharmacokinetics of glycyrrhizic acid evaluated by physiologically based pharmacokinetic modeling. Drug Metab Rev 2001 33 125-147
25. Rubis B, Krozowski Z, Trzeciak WH. Arginine vasopressin stimulates 11beta-hydroxysteroid dehydrogenase type 2 expression in the mineralocorticosteroid target cells. Mol Cell Endrocrinol 2006 256 17-22
26. Sandeep TC, Andrew R, Homer NZM et al. Increased in-vivo regeneration of cortisol in adipose tissue in human obesity and effects of the 11-hydroxysteroid dehydrogenase type 1 inhibitor carbenoxolone. Diabetes 2005 54 872-879
27. Schwartz MW, Kahn SE. Insulin resistance and obesity. Nature 1999 402 860-861
28. Shimoyama Y, Hirabyashi K, Matsumoto H et al. Effects of glycyrrhetinic acid derivatives on hepatic and renal 11-hydroxysteroid dehydrogenase activities in rats. J Pharm Pharmacol 2003 55 811-817
29. Steward PM. 11- Hydroxysteroid dehydrogenase: Implications for clinical medicine. Clin Endocrinol 1996 44 493-499
30. y Mice. Biol Pharm Bull 2001 24 484-487
31. Tanahashi T, Mune T, Morita H et al. Glycyrrhizic acid suppresses type 2 11-hydroxysteroid dehydrogenase expression in vivo. J Steroid Biochem Mol Biol 2002 80 441-447
32. Tomlinson JW, Walker EA, Bujalska IJ et al. 11-hydroxysteroid dehydrogenase type 1: A tissue-specific regulator of glucocorticoid response. Endocrine Rev 2004 25 (5) 831-866
33. van Wijk JPH, Cabezas MC, de Koning EJP et al. Rosiglitazone imporves postprandialtriglyceride and free fatty acid metabolism in type 2 diabetes. Diabetes Care 2005 28 (4) 844-849
34. Wallace TM, Levy JC, Matthew DR. use and abuse of HOMA modeling. Diabetes Care 2004 27 (6) 1487-1495
35. Whorwood CB, Donovan SJ, Flanagan D et al. Increased glucocorticoid receptor expression in human skeletal muscle cells may contribute to the pathogenesis of the metabolic syndrome. Diabetes 2002 51 1066-1075